Arabic Arabic English English French French German German
dark

Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant

Adjuvance Technologies Inc. announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Johns Hopkins develops Epic-embedded tool to better support telehealth patients

Next Post

Verizon Business streamlines patient care with advances to BlueJeans Telehealth

Related Posts
Total
0
Share